pheochromocytoma and paraganglioma pcpg epidemiology forecast
Pheochromocytoma and Paraganglioma (PCPG) Insights and Trends
- According to DelveInsight’s analysis, the total incident cases PCPG were approximately 4,900 in the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- Approximately 10% of pheochromocytomas and 40% of paragangliomas are classified as malignant. Germline genetic mutations have been identified in roughly 30% of patients. Certain mutations, especially those affecting the SDHx genes, are associated with a higher probability of malignant transformation.
- The age-related rise in PCPG burden reflects the greater likelihood of tumor detection in middle-aged and older adults, driven by the cumulative impact of genetic susceptibility, prolonged exposure to physiological stressors, and the increasing use of advanced diagnostic imaging. In addition, routine abdominal imaging and endocrine evaluations in older populations frequently identify adrenal incidentalomas, contributing to a higher concentration of diagnosed cases in later decades of life compared with younger age groups.
- PCPGs predominantly present as localized tumors, with only a minority progressing to metastatic disease. Metastatic potential is influenced by tumor location, genetic mutations (e.g., SDHB), and other biological factors, making these cases more aggressive. Most patients maintain organ confined disease, which is associated with better prognosis and treatment outcomes. The contrast between localized and metastatic cases highlights the clinical and molecular heterogeneity inherent to PCPG.
Pheochromocytoma and Paraganglioma (PCPG) Epidemiology Forecast in the 7MM
- 2025 Incident Cases of PCPG: ~4,900
- 2036 Projected Incident Cases of PCPG: ~5,650
- PCPG Growth Rate (2026–2036): 1.3% CAGR
DelveInsight's ‘Pheochromocytoma and Paraganglioma (PCPG) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the PCPG, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
- North America : The US;
- Europe: Germany, France, Italy, and Spain and the UK;
- Asia-Pacific: Japan
|
|
PCPG Epidemiology CAGR
(Forecast period)
|
1.3% (2026–2036)
|
|
PCPG Epidemiology Segmentation Analysis
|
Patient Burden Assessment
- Total Incident Cases of PCPG
- Occurrence or Absence of Mutation in PCPG
- Age-specific Incident Cases of PCPG
- Stage-specific Incident Cases of PCPG
|
Pheochromocytoma and Paraganglioma (PCPG) Understanding and Diagnosis Algorithm
Pheochromocytoma and Paraganglioma (PCPG) Overview and Diagnosis
PCPGs are rare neuroendocrine tumors (NETs) arising from neural crest–derived chromaffin cells. Pheochromocytomas originate in the adrenal medulla and typically secrete catecholamines (epinephrine and norepinephrine), causing characteristic clinical symptoms. While paragangliomas arise from extra-adrenal paraganglia located along the sympathetic and parasympathetic nervous systems throughout the body.
Further details are provided in the report.
Pheochromocytoma and Paraganglioma (PCPG) Diagnosis
Diagnosis of PCPG primarily involves biochemical testing followed by imaging confirmation. The initial step is measuring plasma free metanephrines or 24-hour urinary fractionated metanephrines, which are highly sensitive markers of catecholamine excess produced by these tumors. If biochemical results are elevated, imaging studies such as CT or MRI are performed to localize the tumor, while functional imaging (e.g., MIBG scintigraphy or PET scans) may be used to detect metastatic or extra-adrenal disease. Genetic testing is also recommended for many patients, as a significant proportion of PCPG cases are associated with hereditary syndromes.
Further details are provided in the report.
Pheochromocytoma and Paraganglioma (PCPG) Epidemiology
Key Findings from PCPG Epidemiological Analysis and Forecast
- According to DelveInsight’s estimates, in 2025, the total number of incident cases of PCPG in the 7MM were ~4,900.
- In the US, germline or somatic mutations accounted for ~1,800 cases in 2025, while the ~600 cases were associated with tumors with no genetic alterations.
- In Japan, the highest number of age-specific incident PCPG cases in 2025 was observed in the 50–74 years age group (~340 cases), while individuals aged under 25 years accounted for the lowest number of cases (~46).
- In the US, localized PCPG accounted for the majority of diagnoses compared with metastatic disease, reflecting the tendency for most tumors to be detected before distant spread, although all PCPGs retain metastatic potential.
Scope of the Report
- The report covers a segment of a descriptive overview of PCPG, explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- Pheochromocytoma and Paraganglioma (PCPG) Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs
- What are the disease risks, burdens, and unmet needs of PCPG? What will be the growth opportunities across the 7MM concerning the patient population with PCPG?
- What is the historical and forecasted PCPG patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Methodology of Pheochromocytoma and Paraganglioma (PCPG)
5. Pheochromocytoma and Paraganglioma (PCPG) Epidemiology Overview at a Glance
5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background And Overview of Pheochromocytoma and Paraganglioma (PCPG)
6.1. Introduction
6.2. Types of PCPG
6.3. Molecular Classification of PCPG
6.4. Causes
6.5. Signs And Symptoms
6.6. Diagnosis
6.6.1. Differential Diagnosis
6.6.2. Diagnostic Algorithm
6.6.3. Diagnostic Guidelines
6.6.3.1. NCCN Guidelines for Diagnosis of PCPG (2025)
6.6.3.2. International Expert Consensus Statement on Management of PCPG in Patients With Germline SDHB Pathogenic Variants (2024)
6.6.3.3. North American Neuroendocrine Tumor Society (NANETS) Guidelines (2022)
6.6.3.4. European Standard Clinical Practice (ESCP) (2025)
6.6.3.5. Japan Endocrine Society Clinical Practice Guideline (2025)
7. Epidemiology and Patient Population of Pheochromocytoma and Paraganglioma (PCPG)
7.1. Key Findings
7.2. Assumption and Rationale
7.3. Total Incident Cases of PCPG in the 7MM
7.4. The United States
7.1. Total Incident Cases of PCPG in the United States
7.4.2. Occurrence or Absence of Mutation in PCPG in the United States
7.4.3. Age-specific Incident Cases of PCPG in the United States
7.4.4. Stage-specific Incident Cases of PCPG in the United States
7.5. EU4 and the UK
7.5.1. Total Incident Cases of PCPG in EU4 and the UK
7.5.2. Occurrence or Absence of Mutation in PCPG in EU4 and the UK
7.5.3. Age-specific Incident Cases of PCPG in EU4 and the UK
7.5.4. Stage-specific Incident Cases of PCPG in EU4 and the UK
7.6. Japan
7.6.1. Total Incident Cases of PCPG in Japan
7.6.2. Occurrence or Absence of Mutation in PCPG in Japan
7.6.3. Age-specific Incident Cases of PCPG in Japan
7.6.4. Stage-specific Incident Cases of PCPG in Japan
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables:
List of Table
Table 1: Summary of PCPG Epidemiology (2025–2036)
Table 2: Recommendations for Diagnosis of PCPG
Table 3: Recommendations for Diagnosis of PCPG
Table 4: Reccommendations for Physical Examination of PCPG
Table 5: Recommended Biochemical Testing in Pediatric Paraganglioma
Table 6: Recommendations for Diagnosis of PCPG
Table 7: Recommendations for Diagnosis of Head and Neck Paragangliomas
Table 8: Recommendations for Diagnosis of PCPG in Pregnancy and Children
Table 9: Total Incident Cases of PCPG in the 7MM (2022–2036)
Table 10: Total Incident Cases of PCPG in the United States (2022–2036)
Table 11: Occurrence or Absence of Mutation in PCPG in the United States (2022–2036)
Table 12: Age-specific Incident Cases of PCPG in the United States (2022–2036)
Table 13: Stage-specific Incident Cases of PCPG in the United States (2022–2036)
Table 14: Total Incident Cases of PCPG in EU4 and the UK (2022–2036)
Table 15: Occurrence or Absence of Mutation in PCPG in Germany (2022–2036)
Table 16: Occurrence or Absence of Mutation in PCPG in France (2022–2036)
Table 17: Occurrence or Absence of Mutation in PCPG in Italy (2022–2036)
Table 18: Occurrence or Absence of Mutation in PCPG in Spain (2022–2036)
Table 19: Occurrence or Absence of Mutation in PCPG in the UK (2022–2036)
Table 20: Occurrence or Absence of Mutation in PCPG in EU4 and the UK (2022–2036)
Table 21: Age-specific Incident Cases of PCPG in Germany (2022–2036)
Table 22: Age-specific Incident Cases of PCPG in France (2022–2036)
Table 23: Age-specific Incident Cases of PCPG in Italy (2022–2036)
Table 24: Age-specific Incident Cases of PCPG in Spain (2022–2036)
Table 25: Age-specific Incident Cases of PCPG in the UK (2022–2036)
Table 26: Age-specific Incident Cases of PCPG in EU and the UK (2022–2036)
Table 27: Stage-specific Incident Cases of PCPG in Germany (2022–2036)
Table 28: Stage-specific Incident Cases of PCPG in France (2022–2036)
Table 29: Stage-specific Incident Cases of PCPG in Italy (2022–2036)
Table 30: Stage-specific Incident Cases of PCPG in Spain (2022–2036)
Table 31: Stage-specific Incident Cases of PCPG in the UK (2022–2036)
Table 32: Stage-specific Incident Cases of PCPG in EU4 and the UK (2022–2036)
Table 33: Total Incident Cases of PCPG in Japan (2022–2036)
Table 34: Occurrence or Absence of Mutation in PCPG in Japan (2022–2036)
Table 35: Age-specific Incident Cases of PCPG in Japan (2022–2036)
Table 36: Stage-specific Incident Cases of PCPG in Japan (2022–2036)
List of Figures:
List of Figures
Figure 1: Anatomical Location of PCPG
Figure 2: Signs and symptoms of PCPG
Figure 3: Cluster-wise Diagnostic Algorithm
Figure 4: NCCN Guidelines for Diagnosis of PCPG
Figure 5: Total Incident Cases of PCPG in the 7MM (2022–2036)
Figure 6: Total Incident Cases of PCPG in the United States (2022–2036)
Figure 7: Occurrence or Absence of Mutation in PCPG in the United States (2022–2036)
Figure 8: Age-specific Incident Cases of PCPG in the United States (2022–2036)
Figure 9: Stage-specific Incident Cases of PCPG in the United States (2022–2036)
Figure 10: Total Incident Cases of PCPG in EU4 and the UK (2022–2036)
Figure 11: Occurrence or Absence of Mutation in PCPG in EU4 and the UK (2022–2036)
Figure 12: Age-specific Incident Cases of PCPG in EU4 and the UK (2022–2036)
Figure 13: Stage-specific Incident Cases of PCPG in EU4 and the UK (2022–2036)
Figure 14: Total Incident Cases of PCPG in Japan (2022–2036)
Figure 15: Occurrence or Absence of Mutation in PCPG in Japan (2022–2036)
Figure 16: Age-specific Incident Cases of PCPG in Japan (2022–2036)
Figure 17: Stage-specific Incident Cases of PCPG in Japan (2022–2036)
